Vimarsana
Biggest News Aggregation in the World

Page 16 - Acceleron Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Acceleron Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Acceleron Pharma Today - Breaking & Trending Today

U.S. FDA Accepts for Priority Review Supplemental Biologics License Application and EMA Validates Ap - Vimarsana News

U.S. FDA Accepts for Priority Review Supplemental Biologics License Application and EMA Validates Ap

Applications based on results from Phase 3 COMMANDS study in which first-in-class Reblozyl demonstrated a highly statistically significant and clinically meaningful improvement compared to an erythropoiesis-stimulating agent in patients with very low/low/intermediate-risk MDSU.S. FDA has assigned a target action dat...

Bristol Myers Squibb Reports First Quarter Financial Results for 2023 - Vimarsana News

Bristol Myers Squibb Reports First Quarter Financial Results for 2023

Reports First Quarter Revenues of $11.3 Billion Posts First Quarter GAAP Earnings Per Share of $1.07 and Non-GAAP EPS of $2.05; Includes Net Impact of Per Share for GAAP and Non-GAAP EPS Due to... | April 27, 2023

Merck's Earnings Are Thursday. This Is What to Expect. - Vimarsana News

Merck's Earnings Are Thursday. This Is What to Expect.

The big pharma company has been getting ready for the loss of patent protection for the cancer immunotherapy Keytruda in 2028.

Merck's $11B Prometheus Acquisition Brings IBD Drug & Precision Medicine Platform - Vimarsana News

Merck's $11B Prometheus Acquisition Brings IBD Drug & Precision Medicine Platform

Merck is acquiring Prometheus Biosciences and a lead drug candidate in development for inflammatory bowel disorders. The deal comes as Merck looks for drug prospects that could make up for revenue declines facing blockbuster seller Keytruda, which faces patent expirations in coming years.

Merck to buy inflammatory disease drugmaker Prometheus for $10.8B - Vimarsana News

Merck to buy inflammatory disease drugmaker Prometheus for $10.8B

BioPharma